Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESILIENT: Onivyde vs Topotecan in SCLC
NCT03088813Phase 3Completed
- Sponsor
- Ipsen
- Start
- Apr 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of irinotecan liposome injection in small cell lung cancer (SCLC), sponsored by Ipsen. Started Apr 2018; status: completed.
02
Drugs
irinotecan liposome injection
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03088813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03088813.